30349860|t|Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory.
30349860|a|OBJECTIVE: The prognostic value of cerebrospinal fluid neurofilament light chain, total tau, phosphorylated tau181, and amyloid beta1-42 was examined in frontotemporal dementia subtypes. METHODS: We compared baseline biomarkers between 49 controls, 40 patients with behavioral variant frontotemporal dementia, 24 with semantic variant primary progressive aphasia, and 26 with nonfluent variant primary progressive aphasia. Linear mixed effect models were used to assess the value of baseline biomarkers in predicting clinical and radiographic change in patient cohorts over multiple yearly follow up visits. RESULTS: Neurofilament light chain concentrations were lowest in controls. Elevated baseline neurofilament light chain predicted faster worsening in clinical severity, frontotemporal volume and frontotemporal fractional anisotropy in patients with behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. High total tau similarly predicted faster progression in nonfluent variant primary progressive aphasia. In behavioral variant frontotemporal dementia, higher phosphorylated tau181 predicted faster clinical progression whereas lower amyloid beta1-42 predicted faster volumetric and fractional anisotropy reduction. Neurofilament light chain and phosphorylated tau181 were of greater predictive value in patients with tau pathology as compared to TDP-43 pathology. Baseline neurofilament light chain correlated with baseline clinical severity and frontotemporal volume in behavioral variant frontotemporal dementia. Baseline total tau correlated with baseline clinical severity in semantic variant primary progressive aphasia. INTERPRETATION: High cerebrospinal fluid neurofilament light chain predicts more aggressive disease in behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. Total tau, phosphorylated tau181, and amyloid beta1-42 also predict some measures of disease aggressiveness in frontotemporal dementia.
30349860	39	62	frontotemporal dementia	Disease	MESH:D057180
30349860	163	166	tau	Gene	4137
30349860	228	251	frontotemporal dementia	Disease	MESH:D057180
30349860	327	335	patients	Species	9606
30349860	341	383	behavioral variant frontotemporal dementia	Disease	MESH:D057180
30349860	410	437	primary progressive aphasia	Disease	MESH:D018888
30349860	469	496	primary progressive aphasia	Disease	MESH:D018888
30349860	628	635	patient	Species	9606
30349860	917	925	patients	Species	9606
30349860	931	973	behavioral variant frontotemporal dementia	Disease	MESH:D057180
30349860	996	1023	primary progressive aphasia	Disease	MESH:D018888
30349860	1036	1039	tau	Gene	4137
30349860	1100	1127	primary progressive aphasia	Disease	MESH:D018888
30349860	1132	1174	behavioral variant frontotemporal dementia	Disease	MESH:D057180
30349860	1427	1435	patients	Species	9606
30349860	1441	1444	tau	Gene	4137
30349860	1470	1476	TDP-43	Gene	23435
30349860	1595	1637	behavioral variant frontotemporal dementia	Disease	MESH:D057180
30349860	1654	1657	tau	Gene	4137
30349860	1721	1748	primary progressive aphasia	Disease	MESH:D018888
30349860	1831	1841	aggressive	Disease	MESH:D010554
30349860	1853	1895	behavioral variant frontotemporal dementia	Disease	MESH:D057180
30349860	1918	1945	primary progressive aphasia	Disease	MESH:D018888
30349860	1953	1956	tau	Gene	4137
30349860	2058	2081	frontotemporal dementia	Disease	MESH:D057180
30349860	Association	MESH:D018888	4137
30349860	Association	MESH:D057180	4137

